|
0
|
|
[(177)Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.
(linkinghub.elsevier.com)
|
Tagawa ST
…
Morris MJ
The Lancet
2026-08-06
|
#prostate cancer
#clinical trial
#radiotherapy
#immunotherapy
|
|
0
|
|
Immunotherapy Efficacy in SMARC-Altered Cancers: A pan-cancer analysis of clinical outcomes in response to immune checkpoint inhibition.
(linkinghub.elsevier.com)
|
Botta GP
…
Kurzrock R
iScience
2026-08-06
|
#cancer
#immunotherapy
#checkpoint_inhibition
#chromatin
#pan-cancer
|
|
0
|
|
Therapeutic outcomes of TP53-mutated diffuse large B cell lymphoma: A systematic review and meta-analysis.
(linkinghub.elsevier.com)
|
Zhou X
…
Shan N
iScience
2026-08-06
|
#lymphoma
#immunotherapy
#chemotherapy
#mutation
#prognosis
|
|
0
|
|
Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial.
(nature.com)
|
Zhang Y
…
Huang G
Nature Medicine
2026-08-06
|
#immunotherapy
#car-t
#glioblastoma
#clinical trial
#oncology
|
|
0
|
|
Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC.
(gut.bmj.com)
|
Gorgulho J
…
von Felden J
Gut
2026-08-06
|
#immunotherapy
#hepatocellular carcinoma
#liquid biopsy
#biomarker
#extracellular vesicles
|